Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 11
Submit an article Journal homepage
68
Views
0
CrossRef citations to date
0
Altmetric
Theme: Hyper- & Hypotension - Review

How will the growing threat of resistant hypertension impact the future treatment of high blood pressure?

Daniel T LacklandDepartment of Neurosciences, Medical University of South Carolina, 19 Hagood Ave, Suite 501,Charleston, SC 29425, USA+1 843 876 [email protected]
Pages 1541-1546 | Published online: 10 Jan 2014

References

  • Society of Actuaries: build and blood pressure study; Vol. 1.Chicago, IL: Society of Actuaries (1959).
  • Freis ED. The role of hypertension. Am. J. Public Health Nations Health 50(3)(Pt 2),11–13 (1960).
  • Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch. Intern. Med. 153(5), 598–615 (1993).
  • Flack JM, Neaton J, Grimm R Jr et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple risk factor intervention trial research group. Circulation 92(9), 2437–2445 (1995).
  • Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
  • Kuller LH. Epidemiology and prevention of stroke, now and in the future. Epidemiol. Rev. 22(1), 14–17 (2000).
  • Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988–1991. Hypertension 25(3), 305–313 (1995).
  • Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290(2), 199–206 (2003).
  • Roccella EJ; The National High Blood Pressure Education Program. Companion to Brenner and Rector’s The Kidney. In: Hypertension (2nd Edition). Oparil S, Weber MA( Eds). Elsevier Saunders, Philadelphia, USA (2005).
  • Wright JD, Hughes JP, Ostchega Y. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001–2008. Natl. Health Stat. Report. (35), 1–22, 24 (2011).
  • Yoon SS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999–2008. NCHS Data Brief. (48), 1–8 (2010).
  • He J, Whelton PF. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am. Heart J. 138(3 Pt. 2),211–219 (1999).
  • Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 237(3), 255–261 (1977).
  • The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 140(10), 1280–1285 (1980).
  • The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 148(5), 1023–1038 (1988).
  • The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 144(5), 1045–1057 (1984).
  • The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch. Intern. Med. 153(2), 154–183 (1993).
  • The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157(21), 2413–2446 (1997).
  • Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
  • Handler J, Lackland DT. Translation of hypertension treatment guidelines into practice: a review of implementation. J. Am. Soc. Hypertens. 5(4), 197–207 (2011).
  • Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC. Scientific evidence underlying the ACC/AHA clinical guidelines. JAMA301(8), 831–841 (2009).
  • de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57(5), 898–902 (2011).
  • Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertensionin hypertensive patients. Circulation 125, 1635–1642 (2012).
  • Calhoun DA, Jones D, Textor S et al. American heart association professional education committee. American heart association scientific statement: resistant hypertension: diagnosis, evaluation and treatment. Circulation 51(6), 1403–1419 (2008).
  • Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 125(13), 1594–1596 (2012).
  • Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation124(9), 1046–1058 (2011).
  • Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 57, 1076–1080 (2011).
  • Acelajado MC, Pisoni R, Dudenbostel T et al. Refractory hypertension: definition, prevalence, and patient characteristics. J. Clin. Hypertens. (Greenwich) 14(1), 7–12 (2012).
  • Cuspidi C, Macca G, Sampieri L et al. High prevalence of cardiac and extra cardiac target organ damage in refractory hypertension. J. Hypertens. 19(11),2063–2070 (2001).
  • Muxfeldt ES, Fiszman R, de Souza F, Viegas B, Oliveria FC, Salles GF. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 59(2),384–389 (2012).
  • Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension48(5),846–852 (2006).
  • Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N. Engl. J. Med. 339(27), 1957–1963 (1998).
  • Amar J, Chamontin B, Genes N et al. Why is hypertension so frequently uncontrolled in secondary prevention? J. Hypertens.21(6), 1199–1205 (2003).
  • Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54(3), 475–481 (2009).
  • Chan CC, Reid CM, Aw TJ et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J. Hypertens. 27 (12), 2332–2341 (2009).
  • Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
  • Setaro JF, Black HR. Refractory hypertension. N. Engl. J. Med. 327 (8), 543–547 (1992).
  • Fugh-Berman A. Herb-drug interactions. Lancet 355 (9198), 134–138 (2000).
  • Licht CM, de Geus EJ, Seldenrij kA et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 53(4), 631–638 (2009).
  • Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 168(11), 1159–1164 (2008).
  • Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39(5), 982–988 (2002).
  • Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628), 1921–1926 (2008).
  • Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (6), 892–896 (2002).
  • Eide IK, Torjesen PA, Drolsum A et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22(11), 2217–2226 (2004).
  • Gonçalves SC, Martinez D, Gus M et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 132(6), 1858–1862 (2007).
  • Logan AG, Perlikowski SM, Mente A et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J. Hypertens. 19(12), 2271–2270 (2001).
  • Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest131(2),453–459 (2007).
  • Mejia AD, Egan BM, Schork NJ, Zweifler AJ. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann. Intern. Med. 112(4),270–277 (1990).
  • Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am. J. Hypertens. 18(12 Pt. 1), 154–1540 (2005).
  • Mancia G, Parati G, Pomidossi G et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9(2), 209–215 (1987).
  • Mancia G,Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension. J. Hypertens. 31(7), 1281–1357 (2013).
  • National Clinical Guideline Centre (NCGC). Clinical management of primary hypertension in adults. clinical guideline 127. methods, evidence and recommendations. In: Hypertension, London, UK (2011).
  • Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 345, e7473 (2012).
  • Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J. Hypertens. 30(8), 1656–1664 (2012).
  • DiBona GF. Neural control of the kidney: past, present, and future. Hypertension 41(3 Pt. 2), 621–624 (2003).
  • Brinkman J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to- control hypertensive patients: prospective case series. Hypertension 60(6), 1485–1490 (2012).
  • Mahfoud F, Cremers B, Janker J et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2),419–424 (2012).
  • Hering D, Lambert EA, Marusic P et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 61(2), 457–464 (2013).
  • Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; for the Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25), 2976–2982 (2012).
  • Lambert GW, Hering D, Esler MD et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension 60(6),1479–1484 (2012).
  • Iliescu R, Irwin ED, Georgakopoulos D, Lohmeier TE. Renal responses to chronic suppression of central sympathetic outflow. Hypertension 60(3),749–756 (2012).
  • Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension 60(3),653–658 (2012).
  • Linz D, Mahfoud F, Schotten U et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 60(1),172–178 (2012).
  • Irvin MR, Shimbo D, Mann DM et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J. Clin. Hypertens. 14(10),694–700 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.